Patrick Cramer
Auto-generated profile, based on publicly available information

Patrick Cramer

Department of Molecular Biology, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
DTDimitry Tegunov
Dimitry Tegunov
PCPatrick Cramer
Patrick Cramer

21 May 2020 in Nature
Verified
Journal Article
Closed access
HHHauke S. Hillen
Hauke S. Hillen
GKGoran Kokic
Goran Kokic
LFLucas Farnung
Lucas Farnung
CDChristian Dienemann
Christian Dienemann
DTDimitry Tegunov
Dimitry Tegunov
PCPatrick Cramer
Patrick Cramer

28 August 2019 in Nature
Verified
Journal Article
Closed access
PDF file
PCPatrick Cramer
Patrick Cramer

11 August 2021 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
FKFlorian Kabinger
Florian Kabinger
CSCarina Stiller
Carina Stiller
JSJana Schmitzová
Jana Schmitzová
CDChristian Dienemann
Christian Dienemann
GKGoran Kokic
Goran Kokic
PCPatrick Cramer
Patrick Cramer
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans. Here, we establish the molecular mechanisms underlying molnupiravir-induced RNA mutagenesis by the viral RNA-dependent RNA polymerase (RdRp). Biochemical assays show that the RdRp uses the active form of molnupiravir, β-d-N4-hydroxycytidine (NHC) triphosphate, as a substrate instead of cytidine triphosphate or uridine triphosphate. When the RdRp uses the resulting RNA as a template, NHC directs incorporation of either G or A, leading to mutated RNA products. Structural analysis of RdRp–RNA complexes that contain mutagenesis products shows that NHC can form stable base pairs with either G or A in the RdRp active center, explaining how the polymerase escapes proofreading and synthesizes mutated RNA. This two-step mutagenesis mechanism probably applies to various viral polymerases and can explain the broad-spectrum antiviral activity of molnupiravir.

20 August 2018 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
MBMarc Boehning
Marc Boehning
CDClaire Dugast-Darzacq
Claire Dugast-Darzacq
MRMarija Rankovic
Marija Rankovic
AHAnders S. Hansen
Anders S. Hansen
TYTaekyung Yu
Taekyung Yu
MZMarkus Zweckstetter
Markus Zweckstetter

12 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GKGoran Kokic
Goran Kokic
HHHauke S. Hillen
Hauke S. Hillen
DTDimitry Tegunov
Dimitry Tegunov
CDChristian Dienemann
Christian Dienemann
FSFlorian Seitz
Florian Seitz
PCPatrick Cramer
Patrick Cramer
Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls. Here we use synthetic RNA chemistry, biochemistry and cryo-electron microscopy to establish the molecular mechanism of remdesivir-induced RdRp stalling. We show that addition of the fourth nucleotide following remdesivir incorporation into the RNA product is impaired by a barrier to further RNA translocation. This translocation barrier causes retention of the RNA 3ʹ-nucleotide in the substrate-binding site of the RdRp and interferes with entry of the next nucleoside triphosphate, thereby stalling RdRp. In the structure of the remdesivir-stalled state, the 3ʹ-nucleotide of the RNA product is matched and located with the template base in the active center, and this may impair proofreading by the viral 3ʹ-exonuclease. These mechanistic insights should facilitate the quest for improved antivirals that target coronavirus replication.